Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1960 1
1963 3
1964 1
1965 1
1970 1
1971 3
1975 2
1978 1
1979 1
1989 1
1990 2
1991 3
1992 2
1993 2
1994 4
1995 4
1996 2
1997 5
1998 3
1999 2
2001 7
2002 3
2003 4
2004 12
2005 12
2006 26
2007 18
2008 18
2009 12
2010 19
2011 22
2012 16
2013 26
2014 25
2015 23
2016 16
2017 17
2018 13
2019 22
2020 20
2021 33
2022 22
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA. Elliott J, et al. Among authors: hsieh sc. PLoS One. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584. eCollection 2020. PLoS One. 2020. PMID: 33085721 Free PMC article.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
What's wrong with neutrophils in lupus?
Tsai CY, Li KJ, Hsieh SC, Liao HT, Yu CL. Tsai CY, et al. Among authors: hsieh sc. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):684-693. Epub 2018 Nov 19. Clin Exp Rheumatol. 2019. PMID: 30557133 Free article. Review.
412 results